Reply to: letter to the editor "subcutaneous herceptin therapy"
- PMID: 23996383
- DOI: 10.1002/jcph.172
Reply to: letter to the editor "subcutaneous herceptin therapy"
Comment on
-
Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.J Clin Pharmacol. 2013 Feb;53(2):192-201. doi: 10.1177/0091270012436560. J Clin Pharmacol. 2013. PMID: 23436264 Clinical Trial.
-
Subcutaneous herceptin therapy.J Clin Pharmacol. 2013 Dec;53(12):1341-2. doi: 10.1002/jcph.171. Epub 2013 Sep 21. J Clin Pharmacol. 2013. PMID: 23996323 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
